Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 8
Submit an article Journal homepage
358
Views
12
CrossRef citations to date
0
Altmetric
Research Article

Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia

Eunice S. WangRoswell Park Cancer Institute, Buffalo, NY, USACorrespondence[email protected]
,
Karen YeePrincess Margaret Hospital, Toronto, ON, Canada
,
Liang Piu KohNational University Hospital, Singapore
,
Donna HoggeVancouver General Hospital, Vancouver, BC, Canada
,
Sari EnschedeAbbott Laboratories, Abbott Park, IL, USA
,
Dawn M. CarlsonAbbott Laboratories, Abbott Park, IL, USA
,
Matthew DudleyAbbott Laboratories, Abbott Park, IL, USA
,
Keith GlaserAbbott Laboratories, Abbott Park, IL, USA
,
Evelyn McKeeganAbbott Laboratories, Abbott Park, IL, USA
,
Daniel H. AlbertAbbott Laboratories, Abbott Park, IL, USA
,
Xiaohui LiAbbott Laboratories, Abbott Park, IL, USA
,
Rajendra PradhanAbbott Laboratories, Abbott Park, IL, USA
&
Wendy StockUniversity of Chicago, Chicago, IL, USA
 show all
Pages 1543-1551 | Received 02 Dec 2011, Accepted 18 Jan 2012, Published online: 01 Mar 2012

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Caterina Aversa, Francesco Leone, Giorgia Zucchini, Guido Serini, Elena Geuna, Andrea Milani, Donatella Valdembri, Rossella Martinello & Filippo Montemurro. (2015) Linifanib: current status and future potential in cancer therapy. Expert Review of Anticancer Therapy 15:6, pages 677-687.
Read now
Bei Hu, Praveen Vikas, Mohamad Mohty & Bipin N Savani. (2014) Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update. Expert Review of Hematology 7:2, pages 301-315.
Read now

Articles from other publishers (10)

Hend A. A. Ezelarab, Taha F. S. Ali, Samar H. Abbas, Heba A. Hassan & Eman A. M. Beshr. (2023) Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia. BMC Chemistry 17:1.
Crossref
Mahesh Swaminathan, Mai M. Aly, Abdul Moiz Khan, Bayan Al Share, Vikram Dhillon, Enxhi Lalo, Harry Ramos, Katherine G. Akers, Seongho Kim & Suresh Balasubramanian. (2022) Efficacy analysis of different FLT3 inhibitors in patients with relapsed/refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome. eJHaem 4:1, pages 165-173.
Crossref
Jiachen Wen, Siyuan Wang, Rongxian Guo & Dan Liu. (2023) CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment. European Journal of Medicinal Chemistry 245, pages 114884.
Crossref
B. Aydin, H. Beklen, K. Y. Arga, F. Bayrakli & B. Turanli. (2022) Epigenomic and transcriptomic landscaping unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors. Journal of Endocrinological Investigation 46:4, pages 727-747.
Crossref
Krzysztof Koras, Dilafruz Juraeva, Julian Kreis, Johanna Mazur, Eike Staub & Ewa Szczurek. (2020) Feature selection strategies for drug sensitivity prediction. Scientific Reports 10:1.
Crossref
Hao Heng, Yanle Zhi, Haoliang Yuan, Zhijie Wang, Hongmei Li, Shuxian Wang, Jieyi Tian, Haichun Liu, Yadong Chen, Tao Lu, Ting Ran & Shuai Lu. (2019) Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation. European Journal of Medicinal Chemistry 163, pages 195-206.
Crossref
Azam Peyvandipour, Nafiseh Saberian, Adib Shafi, Michele Donato & Sorin Draghici. (2018) A novel computational approach for drug repurposing using systems biology. Bioinformatics 34:16, pages 2817-2825.
Crossref
Caroline Engen, Line Wergeland, Jørn Skavland & Bjørn Gjertsen. (2014) Targeted Therapy of FLT3 in Treatment of AML—Current Status and Future Directions. Journal of Clinical Medicine 3:4, pages 1466-1489.
Crossref
Ahmed Hamed Salem, Denise Koenig & Dawn Carlson. (2013) Pooled Population Pharmacokinetic Analysis of Phase?I, II and III Studies of Linifanib in Cancer Patients. Clinical Pharmacokinetics 53:4, pages 347-359.
Crossref
Yan Xing & Donna E. Hogge. (2013) Combined inhibition of the phosphoinosityl-3-kinase (PI3Kinase) P110δ subunit and mitogen-extracellular activated protein kinase (MEKinase) shows synergistic cytotoxicity against human acute myeloid leukemia progenitors. Leukemia Research 37:6, pages 697-704.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.